Paper Details

  1. Home
  2. Paper Details

Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.

Author: AlvarezMaria Gabriela, ArmentiAlejandro, BertocchiGraciela, LococoBruno, PettiMarcos, ViglianoCarlos, ViottiRodolfo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Chagas disease, caused by the parasite Trypanosoma cruzi, affects approximately 8 million people in Latin America. The main goal of treatment is to prevent the development of cardiomyopathy and transmission via blood transfusion, congenital, or organ transplant. Benznidazole is the only commercially available etiological treatment for Chagas disease. Despite not meeting all ideal drug criteria, it remains in use until better alternatives are developed. The efficacy and tolerance of benznidazole are inversely related to patient age, with side effects being more common in older patients. While systematic evaluation of side effects is mainly done in controlled studies, the actual clinical impact could differ due to the short treatment duration (30-60 days) and single-time administration. This article discusses the benefits and risks of benznidazole treatment from a clinical standpoint for managing chronic adult Chagas disease patients in current medical practice.
Paper Details　
Original Abstract of the Article :
Chagas disease is caused by a parasite, Trypanosoma cruzi, transmitted primarily by a triatomine insect and affects approximately 8 million people in Latin American countries. The principal aim of the management of the disease is to avoid the development of cardiomyopathy and transmission by blood t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/14787210.7.2.157

データ提供：米国国立医学図書館（NLM）

The Side Effects of Benznidazole in Chronic Chagas Disease: A Balancing Act

This research delves into the complexities of treating chronic Chagas disease, a condition caused by the parasite *Trypanosoma cruzi*. The study focuses on the use of benznidazole, the only available medication to target the parasite itself. While benznidazole holds the key to preventing the potentially devastating heart complications of Chagas, it's not without its own challenges. The research explores the delicate balance between the drug's benefits and its side effects, particularly in older patients.

A Closer Look at the Side Effects of Benznidazole

The researchers highlight the need for careful assessment of side effects, especially since benznidazole's effectiveness and tolerance decrease with age. The study underscores the importance of understanding the true clinical impact of these side effects, particularly considering the short duration of treatment.

Navigating the Challenges of Chronic Chagas Disease

This study provides valuable insights into the management of chronic Chagas disease. It reminds us that treating this complex condition requires a careful consideration of the benefits and risks associated with available medications. By acknowledging the potential side effects of benznidazole, we can make informed decisions regarding its use and work towards developing more effective and safer treatment options.

Dr.Camel's Conclusion

Chagas disease is a challenging condition, and finding the right balance between treatment benefits and risks is crucial. This research shines a light on the complexities of benznidazole therapy, reminding us that every case is unique. I always say, just like the desert, each patient is a unique landscape waiting to be explored.

Date :
  1. Date Completed 2009-04-09
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

19254164

DOI: Digital Object Identifier

10.1586/14787210.7.2.157

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.